“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
With biotech, is it the destination, the journey, or both? Find out in a new episode of the Biorasi Few & Far Between podcast....
“I think one of the key insights and observations you make when you have a child who's sick and you spend time with other...